United States Patent & Trademark Office (USPTO) has granted Cesca Therapeutics the first two of a family of patent applications related to its proprietary methods for the treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI).

The patents numbered 9,393,269 and 9,402,867 protect important components of Cesca’s SurgWerks technology platform, which is designed for the delivery of autologous regenerative stem cell therapies in a point-of-care environment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The firm previously announced that the SurgWerks platform had been approved by the FDA for use in Cesca’s phase III, pivotal trial for the treatment of late-stage, poor option and no option CLI patients.

“We have been focused on developing and refining our methods for the optimal handling of cells throughout the surgical procedure to ensure their viability and potency.”

Cesca’s director of clinical research Dalip Sethi said: “We have been focused on developing and refining our methods for the optimal handling of cells throughout the surgical procedure to ensure their viability and potency, as well as optimising the delivery method to minimise shear stress on the cells.

“These patents reinforce the initial design and proof-of-concept work related to the use of our SurgWerks platform in a point-of-care setting, further strengthening our intellectual property portfolio as we continue our discussions with the FDA in order to move ahead with our phase III trial for CLI in the near future.”

The patent claims include rapid concentration and delivery of bone marrow derived stem and progenitor cells such as hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs) and CXCR4 positive cells with a reduced amount of red blood cells (RBCs).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The SurgWerks processing platform comprises a smart cell processing module for optically monitored separation and concentration of cell components of interest during centrifugal fractionation.